Pfizer/BioNTech's COVID-19 Vaccine Updated Data Shows Around 76% Efficacy In Toddlers

Pfizer Inc PFE and BioNTech SE BNTX have announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the COVID-19 vaccine in children six months through 4 years of age.

FDA Emergency Use Authorization (EUA) for this age group was given in June. A conditional marketing application is under review by the European Medicines Agency.

Vaccine efficacy was 73.2% among children six months through 4 years of age without evidence of prior COVID-19 infection. 

This analysis was based on 13 cases in the Pfizer-BioNTech COVID-19 Vaccine group (n=794) and 21 cases in the placebo group (n=351). 

The observed cases were primarily caused by omicron BA.2. Omicron BA.4 and BA.5 strains were emerging during the study, with only a few cases accrued. Efficacy results against these strains were inconclusive.

The companies are working with the FDA to prepare a EUA application for an omicron BA.4/BA.5-adapted bivalent vaccine in children six months through 11 years of age.

Among children ages 6 through 23 months, the vaccine was 75.8% effective at preventing COVID-19 and 71.8% for children ages 2 through 4.

Three 3-µg doses of the shot continue to be well-tolerated in this age group. 

Price Action: PFE shares are down 0.29% at $48.76, and BNTX stock is down 0.27% at $147.90 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareTop StoriesGeneralCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!